Compare SKWD & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKWD | ENOV |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Fluid Controls |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.6B |
| IPO Year | 2023 | 2008 |
| Metric | SKWD | ENOV |
|---|---|---|
| Price | $44.39 | $22.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $65.60 | $48.13 |
| AVG Volume (30 Days) | 529.5K | ★ 1.1M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.25 | N/A |
| EPS | ★ 3.37 | N/A |
| Revenue | $1,335,358,000.00 | ★ $2,233,266,000.00 |
| Revenue This Year | $24.24 | $9.22 |
| Revenue Next Year | $30.51 | $4.60 |
| P/E Ratio | $13.11 | ★ N/A |
| Revenue Growth | ★ 22.27 | 11.57 |
| 52 Week Low | $43.35 | $21.00 |
| 52 Week High | $65.05 | $47.26 |
| Indicator | SKWD | ENOV |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 42.32 |
| Support Level | $44.34 | $21.15 |
| Resistance Level | $45.81 | $22.78 |
| Average True Range (ATR) | 1.34 | 1.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 29.88 | 48.78 |
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.